<DOC>
	<DOCNO>NCT00002230</DOCNO>
	<brief_summary>To determine virologic benefit associate addition hydroxyurea ( HU ) combination drug therapy didanosine ( ddI ) , stavudine ( d4T ) , efavirenz ( DMP ) HIV-infected patient . To assess safety tolerance regimen , without HU .</brief_summary>
	<brief_title>A Randomized , Placebo-Controlled Study Safety Efficacy Efavirenz , Didanosine , Stavudine Combination With Without Hydroxyurea Antiretroviral Naive Experienced HIV-Infected Patients</brief_title>
	<detailed_description>HU placebo add 30-60 day initiation DMP , ddI , d4T combination therapy . Patients stratify accord antiretroviral experience ( naive experience ) . Patients follow 48 week determine safety , efficacy , effect treatment viral , immunologic , biochemical parameter .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV infection , document licensed ELISA confirm either Western blot , positive HIV culture , positive HIV antigen , positive plasma HIV RNA , second antibody test positive method ELISA . CD4 cell count least 100 cells/mm3 within 30 day study entry . Over 500 HIV1 RNA copies/ml measure Roche Amplicor Ultra Sensitive Assay within 30 day study entry . Treatmentexperienced patient must document HIV RNA value less equal 100,000 copies/ml within 30 day study entry . Prior Treatment : Excluded : Acute therapy infection medical illness . Acute therapy must complete 14 day prior time study entry . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Malignancy require systemic therapy . Patients follow prior condition exclude : History acute chronic pancreatitis . History generalized peripheral neuropathy . Inability tolerate ddI 200400 mg/day d4T 6080 mg/day . For purpose study , intolerance define recurrent toxicity require dose interruption dose reduction permanent discontinuation drug ( Grade 3 4 anemia ) . Prior Medication : Excluded : Antiretroviral therapy . If antiretroviralexperienced , prior NNRTI 's HU 12 week experience ddI and/or d4T . Protease inhibitor experience allow . Experienced patient must stable antiretroviral therapy 30 day prior study screen continue regimen study entry . Risk Behavior : Excluded : Current ethanol abuse personal history report primary physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Stavudine</keyword>
	<keyword>Hydroxyurea</keyword>
	<keyword>Anti-HIV Agents</keyword>
</DOC>